Norgen Biotek Corp. Announces OEM Manufacturing & Supply Agreement with Exiqon A/S
THOROLD, ON, March 17 /PRNewswire/ - Norgen Biotek, an innovative Canadian biotechnology company focusing primarily on advancing powerful tools for nucleic acids and protein purification, today announced the signing of an OEM agreement with Exiqon
A/S (NASDAQ OMX Copenhagen: "EXQ") to supply RNA p...
Exiqon A/S Announces U.S. Subsidiary Name Change From Oncotech, Inc. to Exiqon Diagnostics, Inc.
COPENHAGEN, October 16 /PRNewswire-FirstCall/ -- Exiqon
the adoption of the name Exiqon
Diagnostics for its U.S. subsidiary to
signal the company's commitment to expanding its business to a broad
offering in molecular and cellular-based diagnostics that guide treatment
Report Regarding the Managements' and Closely Related Parties' Transactions With Securities in Exiqon A/S
VEDBAEK, Denmark, September 2 /PRNewswire-FirstCall/ -- Pursuant to
section 28a of the Danish Securities Trading Act, Exiqon
A/S is required to
publish the managements' and their closely related parties' transactions
with shares and related securities in Exiqon
Exiqon Diagnostics Partners With MedTrust Online to Promote KRAS Mutation Analysis and Other Innovative Molecular Oncology Diagnostic Services to Oncologists
... TUSTIN, Calif., May 29 /PRNewswire/ -- exiqon
Diagnostics, announced today a strategic commercia...owledge on the latest topics in cancer treatment. exiqon
Diagnostics, a leader in individualizing cancer ca...ric oncology portal.
MedTrust Online will add exiqon
Diagnostics service offerings, extensive clinical ...
Interim Report for the Period 1 January - 30 September 2008 (Unaudited)
...EK, Denmark, November 26 /PRNewswire-FirstCall/ -- exiqon
traded at the NASDAQ OMX Copenhagen ("EXQ"), ...hough
the supply problems have now been addressed, exiqon
revises its 2008 total
year guidance of revenue of... - The integration of former Oncotech Inc - now exiqon
Diagnostics Inc -
remains on track for the f...
Exiqon Announces Positive Clinical Data From EORTC Clinical Trial Showing Oncotech EDR Assay Predicts Resistance to Platinum-Based Therapy in Ovarian Cancer
... might benefit the patient."
Dr. Cynthia French, exiqon
Diagnostics Chief Scientific Officer,
stated, "The...ce. The latter is offered to our
customers through exiqon
is a biotech company with activities in three busi...
Exiqon A/S Today Announces a Grant of License to Roche Diagnostics
...To OMX Nordic Exchange Copenhagen and the Press.
A/S today announces a grant of license to Roche Di...lties on future product sales are not disclosed.
retains its financial outlook for 2008 including a...of current incentive plans, including warrants..
maintains its long-term financial goal of profitab...
Exiqon A/S: Interim Report for the Period 1 January - 30 June 2008 (Unaudited)
...ch expected break even by 2011 and on track towards our goal of a cash
flow positive life sciences business by the end of 2009, there is no doubt
is in a sweet spot in the biotechnology market. We see a strong
interest in miRNA and we are very excited about the launch of our first
Exiqon Receives the 2008 Frost & Sullivan Growth Strategy Leadership Award
...-- Frost & Sullivan
has announced the selection of exiqon
as the recipient of its 2008 Growth
Strategy Leade...ent analysis of the molecular diagnostic
was selected for this award because of the company...t & Sullivan viewed the
acquisition of Oncotech by exiqon
as both well-timed and well-executed on
the heels ...
Exiqon Appoints Cynthia French as Chief Scientific Officer and Erik Holmlin as Chief Commercial Officer
... Summary: exiqon
Today Announced the Appointment of Cynthia K. Fren... /PRNewswire-FirstCall/ -- Cynthia K. French
from Affymetrix where she served as Vice President...ncluding the
Erik Holmlin joins exiqon
from BD Diagnostics, GeneOhm, where he held a
miRCURY LNA Northern Blotting Detection probes from Exiqon
Description: Exiqon's miRCURY LNA technology enables sensitive and specific detection of microRNAs (miRNAs) by Northern blotting. miRCURY LNA Detection probes have high binding affinity and discrimination, enabling the specific and sensitive detection of miRNAs. Due to the high binding affinity of the miRCURY L...
miRCURY LNA in situ Detection probes from Exiqon
Description: Exiqon's miRCURY LNA technology enables sensitive and specific detection of microRNAs (miRNAs) by in situ hybridisation. miRCURY LNA in situ detection probes have high binding affinity and discrimination, enabling the specific and sensitive detection of miRNAs. Specific in situ detection of miRNA i...
LNA-ISH Cytogenetics - Human centromere alpha satelliteISH probes from Exiqon
Description: Exiqons LNA technology enables sensitive, fast and specific detection of chromosomal sequences directly on intact chromosomes. Short hybridisation time ( Works on fixed cells and chromosome spreads Multiplex capability Available with different tags Pre-validated probes Probes available w...
Custom LNA Oligonucleotide synthesis from Exiqon
Description: Custom LNA Oligonucleotide synthesis
High quality Custom LNA Oligonucleotides are available for a variety of different specialty applications and innovative products.
Please inquire for further details....
miRCURY LNA Array microarray slides from Exiqon
Description: miRCURY Array LNA microarray slides for microRNA expression profiling
miRCURY LNA Array microarray slides incorporate Exiqons unique Locked Nucleic Acid (LNA) technology to provide unrivalled sensitivity and excellent mismatch discrimination for short microRNA (miRNA) targets. miRCURY LNA Array...